期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 99, 期 2, 页码 164-166出版社
WILEY
DOI: 10.1002/cpt.299
关键词
-
资金
- NIA NIH HHS [U01 AG047109, 1U01AG047109-01] Funding Source: Medline
Although there are several examples in which pharmacogenomic testing seems to provide clinical and economic value, use of pharmacogenomics as a tool to improve drug therapy through routine screening of unselected patients is currently tentative. An informal evaluation of the clinical benefits and economic costs of pharmacogenomic screening suggests that improving the evidence base, addressing uncertainty, and facilitating implementation can lead to practical and cost-effective pharmacogenomic screening programs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据